Overview

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
Phase:
Phase 4
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
Idarubicin
Molgramostim